Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice

Krisztina Herszényi; Hajnalka Jókai; Fanni Rencz; Valentin Brodszky; Eszter Nagy; Péter Holló

doi:10.5114/ada.2019.89507

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2019
vol. 36

Send email

Copy url:

abstract:

Original paper

Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice

Krisztina Herszényi

^{1, 2}

,

Hajnalka Jókai

¹

,

Fanni Rencz

^{3, 4}

,

Valentin Brodszky

⁴

,

Eszter Nagy

⁵

,

Péter Holló

¹

Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
Semmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary
Hungarian Academy of Sciences, Premium Postdoctoral Research Program, Budapest, Hungary
Department of Health Economics, Corvinus University, Budapest, Hungary
National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

Adv Dermatol Allergol 2019; XXXVI (5): 589-594

DOI: https://doi.org/10.5114/ada.2019.89507

Online publish date: 2019/11/12

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Herszényi K, Jókai H, Rencz F, Brodszky V, Nagy E, Holló P. Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2019;36(5):589-594. doi:10.5114/ada.2019.89507.

APA

Herszényi, K., Jókai, H., Rencz, F., Brodszky, V., Nagy, E.,  & Holló, P. (2019). Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 36(5), 589-594. https://doi.org/10.5114/ada.2019.89507

Chicago

Herszényi, Krisztina, Hajnalka Jókai, Fanni Rencz, Valentin Brodszky, Eszter Nagy,  and Péter Holló. 2019. "Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 36 (5): 589-594. doi:10.5114/ada.2019.89507.

Harvard

Herszényi, K., Jókai, H., Rencz, F., Brodszky, V., Nagy, E.,  and Holló, P. (2019). Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 36(5), pp.589-594. https://doi.org/10.5114/ada.2019.89507

MLA

Herszényi, Krisztina et al. "Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 36, no. 5, 2019, pp. 589-594. doi:10.5114/ada.2019.89507.

Vancouver

Herszényi K, Jókai H, Rencz F, Brodszky V, Nagy E, Holló P. Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2019;36(5):589-594. doi:10.5114/ada.2019.89507.

Introduction
Antidrug antibody (ADA) production may be the reason behind secondary inefficacy of anti-TNF-α therapy in psoriasis.

Aim
To investigate the production of ADA, serum tumor necrosis factor α (TNF-α) and drug levels as predictors of clinical response in real-life circumstances.

Material and methods
Serum drug concentrations (TNFi), the presence of ADAs and serum TNF-α levels were measured in 158 patients by the ELISA method. Clinical response was evaluated by calculating PASI. Their correlation has been statistically analysed.

Results
In adalimumab and infliximab treated patients, ADA formation was observed in 18.4% and 33%, respectively, and the serum TNFi concentration was significantly higher in the ADA negative groups. In contrast there was no ADA formation detected among etanercept treated patients. The serum TNFi concentration was significantly lower among non-responders (n = 33). The serum TNF-a level was also measured and the correlation with the concentration of the serum TNFi level was analysed. Having evaluated the results of all patients together, the serum TNFi and TNF-α concentrations showed a significant negative correlation. However, when groups were analysed separately, in case of adalimumab, a significant negative correlation was detected between serum TNFi and TNF-α concentrations. With respect to infliximab, there was no significant correlation, and an inverse correlation was found in the etanercept group. The TNF-α levels and ADA positivity were significantly higher in non-responders.

Conclusions
This study revealed the major role of ADAs against TNFi in case of secondary inefficacy in real-life circumstances. ADA levels show a stronger correlation with PASI failure than serum TNFi or TNF-α levels.

keywords:

Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice

Krisztina Herszényi 1, 2 , Hajnalka Jókai 1 , Fanni Rencz 3, 4 , Valentin Brodszky 4 , Eszter Nagy 5 , Péter Holló 1

psoriasis, tumor necrosis factor α inhibitors, antidrug antibodies, clinical efficacy

Krisztina Herszényi

^{1, 2}

,

Hajnalka Jókai

¹

,

Fanni Rencz

^{3, 4}

,

Valentin Brodszky

⁴

,

Eszter Nagy

⁵

,

Péter Holló

¹